Mylan Labs to expand Hepatitis C deal with Gilead

Hyderabad: City-based Mylan Laboratories Limited, a subsidiary of US-based pharma major Mylan, Inc, on Tuesday said it would expand its Hepatitis C licensing agreement with Gilead Sciences, Inc.

The expanded agreement includes the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir(Sovaldi)/GS-5816. The revised agreement will come into force once the approval is received from 91 developing countries. Currently, the single tablet regimen is being evaluated in Phase 3 clinical studies for the treatment of all six genotypes of hepatitis C. If approved by regulatory authorities, the sofosbuvir/GS-5816 regimen would become the first all-oral single tablet regimen for all hepatitis C genotypes. A pan-genotypic therapeutic option is particularly important for developing countries, where genotype testing is often unreliable or not readily available.

“We are proud to partner with Gilead, once again, in our joint effort to quickly expand access to high quality, affordable medications to the more than 100 million people living with hepatitis C in developing countries,” said Rajiv Malik, President, Mylan.

The potential to offer the sofosbuvir/GS-5816 regimen is particularly exciting, as it is an innovative compound that is being studied to treat all hepatitis C genotypes– a medical advancement that could significantly increase access to treatment, he added.